Abstract
Introduction
Heart valve tissue engineering may provide improved treatment for valvular heart disease, yet development of a tissue engineered heart valve (TEHV) has been limited by incomplete recellularization of the valve leaflets. In this study, we compare the leaflet recellularization potential of candidate cell populations.
Methods
Four cell populations were tested: bone marrow mononuclear cells (MNC), 5 million bone marrow mesenchymal stem cells (MSC), 10 million bone marrow mesenchymal stem cells (MSC2), and 5 million valve interstitial cells (VIC). Candidate cell populations were seeded onto decellularized heart valves and underwent similar conditioning in a low-flow bioreactor for 2 weeks.
Results
MSC2 valves demonstrated the best recellularization of the interstitial leaflet tissue as well as an appropriate cell phenotype, mechanical properties, and biochemical composition. MSC valves exhibited similar leaflet repopulation, yet had decreased mechanical and biochemical properties. MNC seeding resulted in minimal recellularization of the leaflet, though an additional time point group found cells present after 3 days, which seemed to disappear at 2 weeks. VIC seeding resulted in cell clumping on the leaflet surface and poor recellularization.
Conclusions
The results of this study suggest mesenchymal stem cells are a preferred cell population for TEHV recellularization. Additionally, MSCs demonstrate the ability for repopulation of the distal valve leaflet, which will lead to more complete recellularization of future TEHVs.
Similar content being viewed by others
References
Alvarez-Viejo, M., Y. Menendez-Menendez, M. A. Blanco-Gelaz, A. Ferrero-Gutierrez, M. A. Fernandez-Rodriguez, J. Gala, and J. Otero-Hernandez. Quantifying mesenchymal stem cells in the mononuclear cell fraction of bone marrow samples obtained for cell therapy. Transpl. Proc. 45:434–439, 2013.
Blevins, T. L., J. L. Carroll, A. M. Raza, and K. J. Grande-Allen. Phenotypic characterization of isolated valvular interstitial cell subpopulations. J. Heart Valve Dis. 15:815–822, 2006.
Converse, G. L., M. Armstrong, R. W. Quinn, E. E. Buse, M. L. Cromwell, S. J. Moriarty, G. K. Lofland, S. L. Hilbert, and R. A. Hopkins. Effects of cryopreservation, decellularization and novel extracellular matrix conditioning on the quasi-static and time-dependent properties of the pulmonary valve leaflet. Acta Biomater. 8:2722–2729, 2012.
Converse, G. L., E. E. Buse, and R. A. Hopkins. Bioreactors and operating room centric protocols for clinical heart valve tissue engineering. Prog. Pediatr. Cardiol. 35:95–100, 2013.
Converse, G. L., E. E. Buse, K. R. Neill, C. R. McFall, H. N. Lewis, M. C. VeDepo, R. W. Quinn, and R. A. Hopkins. Design and efficacy of a single-use bioreactor for heart valve tissue engineering. J. Biomed. Mater. Res. B 105:249–259, 2015.
Corcione, A., F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia, and A. Uccelli. Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372, 2006.
Dohmen, P. M., S. Hauptmann, A. Terytze, and W. F. Konertz. In-vivo repopularization of a tissue-engineered heart valve in a human subject. J. Heart Valve Dis. 16:447–449, 2007.
Duan, B., L. A. Hockaday, S. Das, C. Xu, and J. T. Butcher. Comparison of mesenchymal stem cell source differentiation toward human pediatric aortic valve interstitial cells within 3D engineered matrices. Tissue Eng. C 21:795–807, 2015.
Filip, D. A., A. Radu, and M. Simionescu. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ. Res. 59:310–320, 1986.
Hoerstrup, S. P., R. Sodian, S. Daebritz, J. Wang, E. A. Bacha, D. P. Martin, A. M. Moran, K. J. Guleserian, J. S. Sperling, S. Kaushal, J. P. Vacanti, F. J. Schoen, and J. E. Mayer, Jr. Functional living trileaflet heart valves grown in vitro. Circulation 102:III44–III49, 2000.
Hof, A., S. Raschke, K. Baier, L. Nehrenheim, J. I. Selig, M. Schomaker, A. Lichtenberg, H. Meyer, and P. Akhyari. Challenges in developing a reseeded, tissue-engineered aortic valve prosthesis. Eur. J. Cardiothorac. Surg. 50:446–455, 2016.
Hopkins, R. From cadaver harvested homograft valves to tissue-engineered valve conduits. Prog. Pediatr. Cardiol. 21:137–152, 2006.
Jana, S., R. T. Tranquillo, and A. Lerman. Cells for tissue engineering of cardiac valves. J. Tissue Eng. Regen. Med. 10:804–824, 2015.
Kurobe, H., S. Tara, M. W. Maxfield, K. A. Rocco, P. S. Bagi, T. Yi, B. V. Udelsman, E. W. Dean, R. Khosravi, H. M. Powell, T. Shinoka, and C. K. Breuer. Comparison of the biological equivalence of two methods for isolating bone marrow mononuclear cells for fabricating tissue-engineered vascular grafts. Tissue Eng. C 21:597–604, 2015.
Lichtenberg, A., I. Tudorache, S. Cebotari, S. Ringes-Lichtenberg, G. Sturz, K. Hoeffler, C. Hurscheler, G. Brandes, A. Hilfiker, and A. Haverich. In vitro re-endothelialization of detergent decellularized heart valves under simulated physiological dynamic conditions. Biomaterials 27:4221–4229, 2006.
Liu, A. C., V. R. Joag, and A. I. Gotlieb. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171:1407–1418, 2007.
Pacelli, S., S. Basu, J. Whitlow, A. Chakravarti, F. Acosta, A. Varshney, S. Modaresi, C. Berkland, and A. Paul. Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration. Adv. Drug. Deliv. Rev. 120:50–70, 2017.
Quinn, R. W., S. L. Hilbert, A. A. Bert, B. W. Drake, J. A. Bustamante, J. E. Fenton, S. J. Moriarty, S. L. Neighbors, G. K. Lofland, and R. A. Hopkins. Performance and morphology of decellularized pulmonary valves implanted in juvenile sheep. Ann. Thorac. Surg. 92:131–137, 2011.
Quinn, R., S. Hilbert, G. Converse, A. Bert, E. Buse, W. Drake, M. Armstrong, S. Moriarty, G. Lofland, and R. Hopkins. Enhanced autologous re-endothelialization of decellularized and extracellular matrix conditioned allografts implanted into the right ventricular outflow tracts of juvenile sheep. Cardiovasc. Eng. Technol. 3:217–227, 2012.
Roh, J. D., R. Sawh-Martinez, M. P. Brennan, S. M. Jay, L. Devine, D. A. Rao, T. Yi, T. L. Mirensky, A. Nalbandian, B. Udelsman, N. Hibino, T. Shinoka, W. M. Saltzman, E. Snyder, T. R. Kyriakides, J. S. Pober, and C. K. Breuer. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc. Natl. Acad. Sci. USA 107:4669–4674, 2010.
Spaggiari, G. M., A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327–1333, 2008.
Steinhoff, G., U. Stock, N. Karim, H. Mertsching, A. Timke, R. R. Meliss, K. Pethig, A. Haverich, and A. Bader. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 102:III50–III55, 2000.
Taylor, P. M., P. Batten, N. J. Brand, P. S. Thomas, and M. H. Yacoub. The cardiac valve interstitial cell. Int. J. Biochem. Cell. Biol. 35:113–118, 2003.
VeDepo, M. C., E. E. Buse, R. W. Quinn, T. Williams, M. S. Detamore, R. A. Hopkins, and G. L. Converse. Species-specific effects of aortic valve decellularization. Acta Biomater. 50:249–258, 2017.
VeDepo, M. C., M. Detamore, R. A. Hopkins, and G. L. Converse. Recellularization of decellularized heart valves: progress toward the tissue-engineered heart valve. J. Tissue Eng. 8:2041731417726327, 2017.
Vincentelli, A., F. Wautot, F. Juthier, O. Fouquet, D. Corseaux, S. Marechaux, T. Le Tourneau, O. Fabre, S. Susen, E. Van Belle, F. Mouquet, C. Decoene, A. Prat, and B. Jude. In vivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates? J. Thorac. Cardiovasc. Surg. 134:424–432, 2007.
Weber, B., J. Scherman, M. Y. Emmert, J. Gruenenfelder, R. Verbeek, M. Bracher, M. Black, J. Kortsmit, T. Franz, R. Schoenauer, L. Baumgartner, C. Brokopp, I. Agarkova, P. Wolint, G. Zund, V. Falk, P. Zilla, and S. P. Hoerstrup. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur. Heart J. 32:2830–2840, 2011.
Acknowledgments
AP acknowledges an investigator grant provided by the Institutional Development Award from the National Institute of General Medical Sciences of the NIH Award Number P20GM103638 and Umbilical Cord Matrix Project fund form the State of Kansas.
Conflict of interest
VeDepo M., Buse E., Paul A., Hopkins R., and Converse G. all declare that they have no conflicts of interest.
Ethical Approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Specifically, ovine aortic valves were harvested from juvenile sheep under approved IACUC protocols and in accordance with Guide for Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23). This article does not contain any studies with human participants performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Associate Editor Michael R. King oversaw the review of this article.
Rights and permissions
About this article
Cite this article
VeDepo, M., Buse, E., Paul, A. et al. Comparison of Candidate Cell Populations for the Recellularization of Decellularized Heart Valves. Cel. Mol. Bioeng. 11, 197–209 (2018). https://doi.org/10.1007/s12195-018-0524-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12195-018-0524-0